NCT07027514View on ClinicalTrials.gov

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2028

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

tolododekin alfa

Participants will receive tolododekin alfa as an intratumoral injection every 3 weeks (Q3W).

DRUG

Cetrelimab

Participants will receive cetrelimab Q3W.

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

Sponsors
All Listed Sponsors
lead

Ankyra Therapeutics, Inc

INDUSTRY